TRPV1 and Parkinson disease: The PD model further confirmed that TRPV1 inhibitors ameliorate motor dysfunction by downregulating the activity of the MAPK/NF-κB pathway in the brain striatum and reducing the expression of pro-inflammatory markers such as COX-2 (111).